Amcor plc (AMCR)

FairStock Score: 49/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett-style investor, I start with the business: Amcor sells packaging into nutrition, health, beauty and wellness end markets, which are relatively steady, but it is a competitive, capital-intensive industry. At the close on 2026-10-13, the price was $41.77 and market cap was $19.3B. The FairStock P/E is 17.55 and P/B is 1.64, not outrageous, but the Graham Number is $36.97, so the margin of safety is negative 12.98%; I am paying above a conservative asset-based value. Financial health is mixed. The Piotroski F-Score of 8/9 is strong, and trailing free cash flow of $1.2B gives a 6.4% FCF yield, which roughly supports the 6.21% dividend yield. But debt-to-equity is 1.28, Altman Z-Score is 0.77, ROE is 9.40% and ROCE is only 3.57%, so the balance sheet and returns do not scream high quality. Filed results show FY2026 revenue of $23.5B, net income of $1.1B and diluted EPS of $2.38, up from FY2025 revenue of $15.0B, net income of $511.0M and EPS of $1.60. Yet FY2024 EPS was higher at $2.52, and fiscal Q4 2025 had a net loss of $39.0M and EPS of negative $0.02. FairStock labels this a slow grower: profit grew 3.3% a year over five years and revenue 12.8%. So I see a steady, cash-generative packaging company with an appealing dividend, but modest returns, leverage, and a price above Graham value keep me cautious.

In plain English: Amcor makes packaging for food, health, beauty and household products around the world. The business throws off cash and pays a high dividend, but profits have been uneven and it carries a fair amount of debt. At the recent price, the shares look a little expensive compared with a conservative estimate of their value, though cash flow gives some support.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q3 2026 10-Q (period ended 2026-03-31) · fiscal Q2 2026 10-Q (period ended 2025-12-31) · fiscal Q1 2026 10-Q (period ended 2025-09-30) · fiscal Q4 2025 10-K (period ended 2025-06-30) · FY2026 10-K (period ended 2026-06-30) · FY2025 10-K (period ended 2025-06-30) · FY2024 10-K (period ended 2024-06-30)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer